These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6542338)

  • 1. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E1 treatment in ductus dependent congenital cardiac malformation. A review of the treatment of 34 neonates.
    Høst A; Halken S; Kamper J; Lillquist K
    Dan Med Bull; 1988 Feb; 35(1):81-4. PubMed ID: 3342648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Care of the infant with ductus-dependent congenital heart disease receiving prostaglandin E1.
    Stachura L
    Issues Compr Pediatr Nurs; 1984; 7(4-5):203-15. PubMed ID: 6569057
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of prostaglandin E1 and E2 in the management of neonatal heart disease.
    Olley PM; Coceani F; Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological manipulation of the ductus arteriosus.
    Silove ED
    Arch Dis Child; 1986 Sep; 61(9):827-9. PubMed ID: 3767410
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.
    Silove ED; Roberts DG; de Giovanni JV
    Arch Dis Child; 1985 Nov; 60(11):1025-30. PubMed ID: 3865636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 9. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
    Roehl SL; Townsend RJ
    Drug Intell Clin Pharm; 1982 Nov; 16(11):823-32. PubMed ID: 6756848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Nonsurgical palliation of congenital heart malformations.
    Olley PM
    N Engl J Med; 1975 Jun; 292(24):1292-4. PubMed ID: 48193
    [No Abstract]   [Full Text] [Related]  

  • 11. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.
    Reddy SC; Saxena A
    Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of prostaglandin in heart abnormalities with needed patency of the arterial canal (clinical and histological study)].
    Moulaert A; Gittenberger-De Groot A; Harinck E
    Arch Fr Pediatr; 1978; 35(7):717-25. PubMed ID: 736728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.
    Lewis AB; Takahashi M; Lurie PR
    J Pediatr; 1978 Sep; 93(3):481-5. PubMed ID: 690772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological and electroencephalographic changes in newborns treated with prostaglandins E1 and E2.
    Fariello R; Olley PM; Coceani F
    Prostaglandins; 1977 May; 13(5):901-7. PubMed ID: 866697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.
    Freed MD; Heymann MA; Lewis AB; Roehl SL; Kensey RC
    Circulation; 1981 Nov; 64(5):899-905. PubMed ID: 7285305
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term prostaglandin E1 therapy in congenital heart defects.
    Teixeira OH; Carpenter B; MacMurray SB; Vlad P
    J Am Coll Cardiol; 1984 Mar; 3(3):838-43. PubMed ID: 6537955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
    Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
    Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.